Apr 23, 2014 7:00 am EDT NeoGenomics Reports Revenue of $18.2 Million and Adjusted EBITDA of $1.7 million for the First Quarter
Mar 18, 2014 7:00 am EDT NeoGenomics Announces Next Generation Sequencing Tests for Solid Tumor Cancers and Myelodysplastic Syndrome
Feb 19, 2014 7:00 am EST NeoGenomics Reports Record Revenue of $18.3 Million, Adjusted EBITDA of $2.7 Million and Net Income of $0.02 per Share for the Fourth Quarter 2013
Jan 30, 2014 7:00 am EST NeoGenomics Launches 22 New Cancer Genomic Tests Designed for Actionable Profiling of Various Hematologic and Solid Cancers
Jan 17, 2014 2:20 pm EST NeoGenomics Schedules its Q4 2013 and Full Year 2013 Earnings Release for February 19, 2014
Jan 7, 2014 7:00 am EST NeoGenomics is the First Laboratory to Offer Calreticulin (CALR) Mutation Testing for the Diagnosis and Classification of Myeloproliferative Neoplasms
Oct 23, 2013 7:00 am EDT NeoGenomics Reports Record Revenue of $16.9 Million, Adjusted EBITDA of $2.2 Million and Net Income of $900K for the Third Quarter 2013
